Axsome Therapeutics Inc
NASDAQ:AXSM
Axsome Therapeutics Inc
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies.
Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies.
Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
Revenue Growth: Axsome's Q4 revenue rose 65% year-over-year to $196 million, with full year revenue up 66% to $639 million.
AUVELITY Momentum: AUVELITY net sales reached $155.1 million in Q4 (up 68% YoY), surpassing $0.5 billion for the year—a 74% YoY increase.
SUNOSI & SYMBRAVO: SUNOSI had $36.7 million in Q4 revenue (up 40% YoY), and SYMBRAVO, in its second full quarter, generated $4.1 million in Q4.
Pipeline Advances: Several late-stage programs progressed, including an sNDA for AUVELITY in Alzheimer’s agitation with an April 30 PDUFA date and the launch of new trials for AXS-05, AXS-12, and solriamfetol.
Sales Force Expansion: The AUVELITY sales force is being doubled to 600 reps to drive primary care growth and support potential Alzheimer’s launch.
Operating Leverage: Revenue grew roughly three times faster than operating expenses in 2025, with management expecting continued leverage into 2026.
Cash Position: Axsome ended the year with $323 million in cash, enough to fund operations until reaching cash flow positive.
